Abstract
Secondary hyperparathyroidism is often associated with end stage renal disease; even after renal transplantation, hyperparathyroidism may persist, and is responsible for hypercalcemia, hypophosphatemia and elevated parathyroid hormone (iPTH) levels. Parathyroid hyperplasia is frequently associated with persistent hyperparathyroidism, and may require a surgical treatment. Here, we report hyperparathyroidism along with parathyroid hyperplasia in a 7-year-old child, which persisted after renal transplant. Calcitonin and pamidronate failed to decrease serum calcium levels; clodronate was also inefficient. Cinacalcet therapy normalized serum calcium and phosphorus levels, and decreased iPTH levels in 3 months; a severe parathyroid hyperplasia was also corrected under calcimimetic therapy. In conclusion, we report in a child that hypercalcemia associated with secondary hyperparathyroidism can be corrected with cinacalcet after pediatric renal transplantation. We also show that parathyroid hyperplasia can regress under calcimimetic therapy in a transplanted child, making surgery unnecessary.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–21.
Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760–71.
Block GA, Zeig S, Sugihara J, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008;23:2311–8.
Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19:1281–7.
Trombetti A, Richert L, Hadaya K, et al. Early post-transplantation hypophosphatemia is associated with elevated FGF-23 levels. Eur J Endocrinol. 2011;164(5):839–47.
Jeon J, Kim H, Yang J. Bone disease in post-transplant patients. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):452–8.
Wolf M, Weir M, Kopyt N, et al. A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation 2015 (epub ahead of print).
Evenepoel P, Cooper K, Holdaas H, et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant. 2014;14:2545–55.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
About this article
Cite this article
Niel, O., Maisin, A., Macher, MA. et al. Cinacalcet in hyperparathyroidism management after pediatric renal transplantation. CEN Case Rep 5, 141–143 (2016). https://doi.org/10.1007/s13730-015-0211-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-015-0211-0